Fluorescent molecularly imprinted nanogels for the detection of anticancer drugs in human plasma by Pellizzoni, Elena et al.
  
 
Fluorescent Molecularly Imprinted Nanogels for the Detection of Anticancer Drugs in 
Human Plasma 
 
Elena Pellizzonia,b, Martina Tommasinia, Elena Marangonc, Flavio Rizzolioc, Gabriele Saitod 
Fabio Benedettia, Giuseppe Toffolic,*, Marina Resminid,*, Federico Bertia,*. 
a: Dipartimento di Scienze Chimiche e Farmaceutiche, Università degli Studi di Trieste, Italy 
(elena.pellizzoni@phd.units.it, martina.tommasini@phd.units.it, benedett@units.it, 
fberti@units.it) 
b: Graduate School of Nanotechnology, Università degli Studi di Trieste, Italy 
c: CRO National Cancer Institute Experimental and Clinical Pharmacology Division, 
Department of Translational Research, Aviano, Italy (frizzolio@cro.it, emarangon@cro.it, 
gtoffoli@cro.it) 
d: Department of Chemistry and Biochemistry, SBCS, Queen Mary University of London, UK 
(g.saito@qmul.ac.uk, m.resmini@qmul.ac.uk) 
 
*Giuseppe Toffoli, Centro di Riferimento Oncologico, IRCCS, Via Franco Gallini 2, 33081 
Aviano, Italy, +39 0434 659235, gtoffoli@cro.it; Federico Berti, Dipartimento di Scienze 
Chimiche e Farmaceutiche, via Giorgieri 1, 34128 Trieste, Italy, +39 040 5583920, 
fberti@units.it; Marina Resmini, Department of Chemistry and Biochemistry, SBCS, Queen 
Mary University of London, Mile End Road, London E1 4NS, UK +44 (0)20 78823268, 
m.resmini@qmul.ac.uk. 
 
 
 
 
 
  
 
Abstract 
Several fluorescent molecularly imprinted nanogels for the detection of the anticancer drug 
sunitinib were synthesized and characterised. A selection of functional monomers based on 
different aminoacids and coumarin allowed isolation of polymers with very good rebinding 
properties and sensitivities. The direct detection of sunitinib in human plasma was successfully 
demonstrated by fluorescence quenching of the coumarin-based nanogels. The plasma sample 
simply diluted in DMSO allowed the recovery of various amounts of sunitib, as determined by 
an averaged calibration curve. The LOD was 400 nM, with within-run variability < 9%, day to 
day  variability < 5%, and good accuracy in the recovery of sunitinib from spiked samples. 
Keywords: therapeutic drug monitoring, anticancer drugs, imprinted polymers, human plasma, 
fluorimetry. 
 
1. Introduction 
Keeping toxicity to a minimal level while ensuring optimal activity and minimal side effects 
are key priorities in cancer therapy, however, individual germ line mutations, in metabolizing 
enzymes, and other pharmacogenomics variations may vary pharmacokinetic and 
pharmacodynamic responses within a pool of individuals. Therapeutic drug monitoring, aimed 
at obtaining personalized medicines, is one of the main targets in current clinical oncology 
(Walko and McLeod 2014; De Jonge at al. 2005; Alnaim 2007). At present, therapeutic drug 
monitoring (TDM) heavily relies on drug extraction and quantification from blood or plasma 
samples by HPLC (Mohammadi et al. 2010) or LC-MS (Marangon et al. 2015; Van Erp et al. 
2013). The instrumentation required for these analyses is expensive and dependent on highly 
specialised personnel, therefore limiting the applicability. The development of a point of care 
device, that allows tailoring of the therapy protocol upon individual responses, with simple 
sample preparation, high sensitivity and good selectivity, remains a challenge.  
  
 
In recent years molecular imprinting has consolidated its place as a viable approach for the 
generation of polymeric matrices with excellent molecular recognition characteristics. The 
templating approach, together with an appropriate choice of functional monomer and cross-
linker, allows the formation of three-dimensional cavities that can rebind the target molecule, 
or its analogues, with high selectivity.  
In the field of therapeutic drug monitoring, imprinted polymers (MIPs) have been developed 
for pre-concentration of samples, as purification cartridges for LC-MS analysis (Thibert et al. 
2014; Yang et al. 2014), or as recognition elements for microbalances, plasmon resonance and 
electrochemical systems (Altintas et al. 2015; Blanco-Lòpez et al. 2004). Alternatively, MIPs 
have also been used as the sensing system, by embedding the signal-generating monomer in the 
polymeric matrix, such as in the case of optical/fluorimetric units (Manju et al. 2010; Awino 
and Zhao 2014; Ton et al. 2013). In terms of polymer matrices, most work has been done with 
bulk polymers, acting as  recognition elements for electrochemical, quantum dots or fiber optic 
based sensors. MIP-based electrochemical sensors have been used to detect uracil- (Prasad et 
al. 2012; Prasad et al. 2009) and anthraquinone-based anticancer drugs (Nezhadali et al. 2016). 
CdTe@SiO2 quantum dots coated with a MIP were used as fluorescent sensor for 
norepinephrine (Wei et al. 2014), and fiber optic array was developed to quantify enrofloxacin 
in sheep serum (Carrasco et al. 2015). 
The main target of this work was to develop fluorescent imprinted nanogels, specific for 
anticancer drugs, that would form stable colloidal solutions when dispersed into human plasma, 
therefore allowing detection of the target with minimal sample preparation.  
  
Plasma is a very complex matrix, containing thousands of different molecules and binding 
proteins such as albumins and immunoglobulins. A potential sensor for the quantification of 
drugs must overcome key issues like the possible cross-reactivity with plasma proteins and 
  
 
small molecules, competitive binding of the drug to albumin, stability issues leading to 
aggregation and precipitation of the nanoparticles.  
For the purpose of this work sunitinib (SU11248, Sutent) 1 (Figure 1) was selected as the target 
drug. Sunitinib is a tyrosine kinase inhibitor used for the treatment of renal cell carcinoma and 
of imatinib-resistant gastrointestinal stromal tumour since 2006 (Noble et al. 2004; Zhang et al. 
2009). It is commonly administered to patients as sunitinib malate, with dosages ranging from 
25-50 mg to 150 mg daily. Pharmacokinetic and pharmacodynamic preclinical studies 
demonstrated that although the therapeutic window of concentrations for sunitinib is between 
50 ng/mL and 500 ng/mL,  concentrations higher than 100 ng/mL result in a significant increase 
in drug toxicity (Faivre et al. 2006; Kollmannsberger et al. 2011). Therefore, the TDM of this 
drug represents a useful system to develop personalized therapies for patients decreasing side 
effects and increasing therapy efficiency. As for other anticancer drugs,  sunitinib quantification 
in plasma is currently performed by HPLC coupled with UV detector (Etienne-Grimaldi et al. 
2009; Blanchet et al. 2009) or mass spectrometer (De Bruijn et al. 2010) or by LC/MS/MS 
methods (Andriamanana et al. 2013). Currently there are no rapid methods available for the 
therapeutic monitoring of sunitinib in alternative to such high specialised equipment, and  point 
of care devices or immunoenzymatic assays for anticancer drugs have yet to be reported.  
 
2. Materials and Methods 
Materials: Sunitinib was purchased from Bepharm ltd. All the other reagents were from 
Sigma-Aldrich.  
Instrumentation: HPLC analyses were run on an Agilent series 1100 liquid chromatograph 
equipped with a Phenomenex, Luna C18 5 column with a column guard and a 20 L loop. 
The flow was set to 1 mL min-1. UV-visible spectra were recorded on a UV-1800 (Shimadzu) 
spectrometer. The fluorescence titrations were performed by a CARY Eclipse (Varian) 
spectrometer with a cuvette of 1 cm optical path, and by a Perkin Elmer LS 50B fluorescence 
  
 
spectrometer. Nuclear magnetic resonance spectra (500 MHz) were recorded on a Varian 500 
spectrometer. Polymeric particles were analysed by Dynamic Laser Light Scattering on a 
Zetasizer  nano-S (Malvern) instrument. 
 
Methyl 2-acrylamido-3-(4-hydroxyphenyl)propanoate (N-acryloyl L-tyrosine methyl ester  
3b): acryloyl chloride (1 mL, 12.3 mmol) in 50 mL anhydrous dichlorometane (DCM) was 
added dropwise, at 0 °C, to a solution of triethylamine (4.5 mL, 32.4 mmol) and L-tyrosine 
methyl ester (2 g, 10.2 mmol)  in 150 mL DCM and the reaction mixture was stirred overnight 
under anhydrous atmosphere. The solvent was removed in vacuo and the crude product was 
purified by silica gel column chromatography (DCM:ethyl acetate from 1:1 to 2.5:7.5) giving 
the product 3b (1.2 g, 47%). White crystals, mp: 125.6 – 129 °C. 1H NMR (500 MHz, CDCl3, 
25°C)  = 3.05 (dd, 2J = 14 Hz, 3J = 9 Hz, 1H), 3.12 (dd, 2J = 14 Hz, 3J = 6 Hz, 1H), 3.75 (s, 
3H), 4.94 (m, 1H), 4.68 (dd, 3J trans = 10 Hz, 
3J cis = 1.2 Hz, 1H), 5.93 (s, 1H), 6.10 (br), 6.09 
(dd, 2J = 17 Hz, 3Jtrans = 10 Hz), 6.29 (dd, 
2Jtrans = 17 Hz,
 3Jcis = 1.2 Hz), 6.73 (d, 
3J = 8.5 Hz, 
2H), 6.94 (d, 3J = 8.5 Hz, 2H). 13C NMR (500 MHz, CDCl3, 25°C)  = 37.27, 52.62, 53.49, 
115.69, 127.41, 127.70, 130.30, 130.51, 152.32, 165.30, 172.27. MS (ESI)  m/z: 272.0 
[M+Na]+; IR:  cm-1 = 1662, 1721 cm-1, 3318. 
 (S)-methyl 2-acrylamido-3-(1H-indol-3-yl)propanoate (N-acryloyl L-tryptophan methyl ester 
4b): acryloyl chloride (0.2 mL, 2.3 mmol) in 5 mL DCM was added dropwise, at 0 °C, to a 
solution of L-tryptophan methyl ester (0.5 g, 1.96 mmol) and triethylamine (0.67 mL, 4.8 mmol) 
in 10 mL anhydrous DCM and the reaction mixture was stirred overnight under anhydrous 
atmosphere. The solvent was removed in vacuo and the crude product was purified by silica gel 
column chromatography (DCM:ethyl acetate from 8:2 to 5:5) giving the product 4b (0.4 g, 
81%). White crystals, mp: 49-49.5 °C. 1H-NMR (500 MHz, d6-DMSO, 25°C) δ = 3.07 (dd, 2J 
= 14.6 Hz, 3J = 8.5 Hz), 3.18 (dd, 2J = 14.6 Hz, 3J = 5 Hz), 3.59 (s, 3H), 4.60 (m, 1H), 5.60 (dd, 
3Jcis = 2 Hz, 
3Jtrans = 10 Hz), 6.07 (dd, 
2J = 17.11 Hz, 3Jcis = 2 Hz), 6.29 (dd, 
2J = 17.11 Hz,  
  
 
3Jtrans = 10Hz, 1H), 6.98 (td, 
3Jortho = 8 Hz, 
4Jmeta = 1 Hz, 1H), 7.06 (td, 
4Jmeta = 1 Hz, 
3Jortho = 4 
Hz, 1H), 7.13 (d, 3J = 2 Hz, 1H), 7.33 (d, 3Jortho = 8 Hz, 1H), 7.49 (d, 
3Jortho = 8 Hz, 1H), 8.54 
(d, 3J = 8 Hz, 1H), 10.85 (s, 1H). 13C-NMR (500 MHz, d6-DMSO, 25°C) δ = 27.79, 52.55, 
53.21, 110.14, 111.41, 118.76, 119.89, 122.41, 122.90, 127.29, 127.82, 130.56, 136.33, 165.13, 
172.38. MS ESI m/z: 295 [M+Na]+; IR:  cm-1= 1662, 1737, 3296. 
2-oxo-2H-chromen-7-yl acrylate (7-O-acryloyl-hydroxycoumarin 5b): acryloyl chloride (0.4 
mL, 4.6 mmol) in 7 mL DCM was added dropwise, at 0 °C, to a solution of  7-hydroxy-
coumarin (0.5 g, 3.08 mmol) and triethylamine (1.26 mL, 9.06 mmol) in 10mL anhydrous DCM 
and the reaction mixture was stirred overnight under anhydrous atmosphere. The reaction 
mixture was extracted with brine, filtered and extracted 3 more times with brine.  The organic 
phase was evaporated in vacuo and the orange residue was purified by flash chromatography 
(DCM : petroleum ether:ethyl acetate 2:1:1) to yield pure 5b (0.6 g,  90%). White crystals, mp: 
136.9-137.5 °C. 1H-NMR (500 MHz, CDCl3, 25°C)  = 6.08 (dd, 3Jtrans = 10.5 Hz, 3Jcis = 1 Hz, 
1H), 6.33 (dd, 3Jtrans = 10.5 Hz,  
2J= 17 Hz, 1H), 6.40 (d, 3Jortho = 9.6 Hz, 1H), 6.65 (dd, 
2J = 17 
Hz, 3Jcis = 1 Hz, 1H), 7.10 (dd, 
3Jortho = 8.4 Hz, 
4Jmeta = 2 Hz, 1H), 7.17 (d, 
4Jmeta = 2 Hz, 1H), 
7.50 (d, 3Jortho = 8.4 Hz, 1H), 7.70 (d, 
3Jortho = 9.6 Hz, 1H). 13C-NMR (500 MHz, CDCl3, 25°C) 
 = 110.57, 116.27, 116.86, 118.49, 127.44, 128.70, 133.82,  142.96, 153.23, 154.85, 160.45, 
163.90.  MS ESI m/z: 238.9 [M+Na]+; IR:  cm-1 = 1734. 
1H NMR titrations 
 Weighted amounts of functional monomer 3b, 4b, 5b were added to a 6.7 mM solution of 
sunitinib in DMSO-d6 so that the concentration of functional monomer varied from 3.35 mM 
to 93.7 mM. Sunitinib (6.7 mM) was also titrated with 4-vinylpyridine (2) using a 1.15 M 
mother solution in DMSO-d6. The 
1H NMR spectrum of the resulting solutions were recorded 
after every addition. (Figure 1). 
 
Synthesis of molecularly imprinted polymers (general procedure) 
  
 
The functional monomer (1 equiv) and the template drug (1.2 equiv) were stirred in DMSO, in 
anhydrous conditions, for 40 minutes. The resulting solution was transferred in a crimp cap 
Wheaton vial and N,N’-ethylenebisacrylamide (crosslinker,  4.7 equiv), recrystallized1 AIBN 
(18% mol, calculated on the amount of the available double bonds, 2.1 equiv) and  acrylamide 
(1equiv) were added. DMSO was adjusted so as to correspond to 99% of total  monomers and 
crosslinker (in weight) and the vial was evacuated, flushed with argon (3 x 10 minutes) and 
then kept at 70°C for 4 days. Each polymer was synthesised both in presence of the template 
molecule, leading to MIP particles, and without the template, leading to NIP (non-imprinted 
polymers). The resulting clear solutions were dialyzed (cut off 3.5 kDa) against methanol for 2 
days and against water for other 2 days, changing the solvent 3 times per day. Finally, the 
solutions were freeze-dried giving a fluffy solid. The composition and quantities of the 
polymerization mixtures for each nanogels are reported in Table S1. The solid polymers were 
reconstituted at the desired concentration by dispersing the nanogels in the required solvent, 
sonnication for 10 minutes and filtration using Micron filter (0.25m pore size). 
Dynamic laser light scattering 
Characterisation of particle size was done in the same solvent system that was used for the 
rebinding assays in plasma. The size distribution by number, intensity and by volume was 
recorded in triplicate for solutions of all MIPs and NIPs (0.25 mg mL-1, 10% H2O in DMSO).  
    
Transmission electron microscopy 
MIP 1.4 (1.08 mg) was dissolved in 2.16 mL of distilled water, the solution was stirred for 10 
minutes and sonicated for 15 minutes. The resulting solution was dialyzed for 24 h at 25°C in 
distilled water using a pre-wetted Float-A-Lyzer® G2 with MWCO = 3.5 - 5.0 kDa (obtained 
                                                 
1 2 g of AIBN were placed in a round-bottomed flask equipped with a stirring bar and a condenser.  The flask was 
evacuated and purged with argon for 10 times, to avoid any trace of oxygen. 5 mL of degassed ethanol were added 
and the temperature was increased slowly to 50-55 °C. 2 mL of ethanol were added to solubilize the product and 
the flask was then left to cool to room temperature to allow crystallization. 
  
 
by Spectrumlabs). The solution was then filtered through a 0.45 μm GHP membrane and a 2.0 
μl were added to graphene oxide grid (GO support film on Lacey carbon on 400 mesh Cu grid, 
Agar Scientific) and imaged at TEM. 
Rebinding tests of the drug  
A mixture of polymer (1.5 mg) and the drug (50 M) in 1.5 mL water was incubated at 25°C 
with continuous stirring; 200 L aliquots were taken after 1 h, 3 h, 8 h and spiked with 50 L 
of a 1 M solution of a reference standard. Each aliquot was centrifuged (10000 rpm for 6 min) 
and the supernatant, containing an unknown amount of the drug and 25 M reference, was 
analysed by HPLC to quantify the drug concentration. The reference standard for sunitinib was 
caffeic acid and the mobile phase was 75 : 25 water : acetonitrile with 0.05% of TFA, 
wavelength: 265 nm.  
Cross reactivity tests with SN38 and paclitaxel were performed in the same manner with 50 µM 
SN38 or paclitaxel in water, using 25 µM quinolinone as reference. SN38 was analysed with 
78 : 22 water : acetonitrile mixture containing 0.05% TFA as the mobile phase, a flux of 1 
mL/min and the detector fixed at 208 nm wavelength. For paclitaxel, 55 : 45 water : acetonitrile 
containing 0.05% TFA was used as the mobile phase  with a flux of 1 mL/min,  and the 
wavelength was set at 230 nm. 
Fluorimetric characterization of the polymers  
  The fluorescence of 60 g/mL solutions of the fluorescent polymers in water containing 3% 
DMSO and sunitinb ranging from 0 to 88.8 M was measured at the following wavelengths: 
303 nm (emission) and 274 nm (excitation) for polymers containing tyrosine;  340 nm 
(emission) and 280 nm (excitation) for polymers containing tryptophan; 456 nm (emission) and 
327 nm (excitation) for polymers containig coumarin. The fluorescence  of solutions of the 
corresponding fluorophores, namely 2.1 M N-Boc-tyrosine, 510 nM  N-Boc-tryptophan, and 
  
 
5 M 7-hydroxy-coumarin, were similarly measured in the presence of sunitinib ranging from 
0 to 73 M.  
 
Fluorescence assay in plasma  
Calibration curve. A 1.0 mg/mL solution of MIP 1.5 in DMSO was diluted to a final 60 µg/mL 
concentration in 4 : 1 DMSO : water. In order to obtain the calibration curve, 400 µL of this 
solution were titrated with increasing amounts of 400 µM and 4 mM sunitinib solutions in 4 : 
1 DMSO-water so that the final sunitinib concentration was in the 1 µM -154 µM range.  
Spiked samples. The spiked samples at 5 µM, 20 µM, 50 µM and 80 µM sunitinib were made 
diluting a 4 mM sunitinib solution with 50 mg/mL HSA in PBS or with plasma to the required 
concentrations. DMSO (400 L) was added to 100 L of this solution and the mixture was 
centrifuged. MIP was added to the supernatant so that the final polymer concentration was 60 
µg/mL and the fluorescence of the solution was measured at the following wavelengths:  456 
nm (emission) and 327 nm (excitation) with bandwidths set at 5 nm. 
 
3. Results and discussion 
   Functional monomers 
The formation of a stable complex between the functional monomer and the template in the 
prepolymerisation mixture is a key requirement in molecular imprinting for obtaining matrices 
with high rebinding characteristics. Four functional monomers were selected for their potential 
ability to interact with Sunitinib, the target drug, via a variety of non-covalent interactions. 
Sunitinib (Figure 1) contains three hydrogen bond donor NH groups, three hydrogen bond 
acceptors (two carbonyls and a tertiary amino group), an extended aromatic system capable of 
π-staking, and four alkyl sites candidates for van der Waals and hydrophobic interactions. 4-
Vinyl pyridine 2 is a functional monomer that may interact by π-π stacking  and hydrogen bonds 
to the nitrogen atom and has been chosen as a reference monomer, being commercially 
  
 
available. N-acryloyl-tyrosine methyl ester 3b and N-acryloyl-tryptophan methyl ester 4b were 
selected to exploit biomimetic recognition of the targets by the amino acid side chains. In 
addition, tryptophan has the advantage of being fluorescent with an emission at 340 nm 
(excitation at 280 nm).  The static quenching of this fluorescence by many interacting molecules 
is often exploited in studies of protein-small molecule interactions (Luisi et al. 2013). 7-
Acryloyloxy-coumarin 5b contains the coumarin fluorophore that emits visible light at 460 nm 
upon excitation at 330 nm: this feature, and its molecular structure, potentially capable of 
establishing π-π stacking interactions with the aromatic regions of Sunitinib, may lead to a light-
emitting sensor that can be switched off when binding the target.  
Compounds 3b, 4b, 5b were obtained by acylation of the corresponding precursors 3a-5a with 
acryloyl chloride following previously reported procedures (Bentolila et al. 2000; Moore and 
O’Relly 2012; Sinkel et al. 2010). 
In order to assess whether compounds 3b-5b can establish strong interactions with the target, a 
series of 1H-NMR titrations were performed in DMSO by adding different concentrations of 
functional monomer to a fixed concentration of sunitinib and monitoring changes in the 
chemical shifts of protons involved in the interaction (Athikomrattanakul et al. 2009). The data 
reported in Figure 1 confirm that Sunitinib interacts with all four functional monomers; its 
indole and methylidene groups make hydrophobic contacts with the aromatic system of 7-
acryloyloxy-coumarin 5b; the formation of hydrogen bonds between the indole NH proton and 
acceptors of N-acryloyl-tryptophan methyl ester 4b and 4-vinyl pyridine 2b is also observed; 
in addition the amide proton of sunitinib is also involved in hydrogen bonding to 4b. The 
interactions with N-acryloyl-tyrosine methyl ester 2b are weaker and involve mainly the amide 
group of sunitinib. The strongest interactions are observed with 5b and 4b, which appear to be 
the most promising monomers. 
  
 
 
Figure 1 (new) 
 
Synthesis and characterization of the polymers 
Nanogels were synthesized by radical copolymerization of the four functional monomers 2b-
5b and acrylamide, with N,N’-ethylenebisacrylamide as the crosslinker, with a total monomer 
concentration (CM) of 1%, in DMSO and AIBN as initiator as reported in Materials and 
Methods. The choice of acrylamide stemmed from the requirement of having polymeric 
matrices capable to easily dissolve as colloids in water. For the imprinted polymers, the 
template and the functional monomers, in a 1.2:1 molar ratio, were allowed to form the complex 
at 25°C for 40 min before polymerization (Pasetto et al. 2005).  Eight nanogels were obtained 
by this method and their composition and characterisation are presented in Table 1. With the 
exception of NIP 0.2, which was poorly soluble, all nanogels showed good solubility and 
formed stable colloidal solutions in a 10% water : DMSO mixture. This solvent system 
appeared to be the most suitable  and was used throughout for the characterisation. The particle 
size was evaluated by dynamic light scattering. The data are presented in  Table 1and figure 
S1 which shows a high degree of consistency with particle size by number all comprised 
  
 
between 8 and 15 nm with good consistency. The results suggest that the polymers are mostly 
found as a fairly homogenous preparation, although the data for size by intensity does suggest 
the presence of a small fraction of aggregated nanoparticles, leading to the high intensity 
scattering around 130 nm diameter on average. However, this fraction was estimated to be less 
than 5% by volume analysis (Long et al. 2011). The particle size were also confirmed by 
transmission electronic microscopy, using graphene oxide grid, and the image for the coumarin-
containing MIP 1.5 is shown in Figure 2.  
 
Figure 2 new 
 
  
 
 The coumarin containing polymers were characterized also by the content of the fluorescent 
tag incorporated, determined by UV, which showed interestingly some significant differences. 
The amount of bound coumarin in NIP 0.5 was found to be 550 pmol/g, over twice the amount 
found in the imprinted material 1.5, which contained 230 pmol/g of the fluorescent label 
(Table S2, Figure S2). This would suggests that the formation of the template-monomer 
complex in the imprinted nanogels significantly impacts the incorporation of the coumarin unit. 
NMR experiments carried out with the coumarin monomer indicate that self-association of the 
monomer occurs at concentrations similar to those used during the nanogel synthesis (11 mM). 
This could explain the higher concentration of coumarin tag found in the non-imprinted 
polymer (Figure S3). The concentration of fluorescent tag in the different polymer preparations 
was taken into consideration when calculations of imprinting efficiency and rebinding were 
carried out. 
Rebinding and selectivity  
Rebinding tests were carried out by HPLC (Table 1). The fluorescent MIP 1.5 is the best binder, 
capturing 35 nmol/mg of the target after several minutes, with good specificity, as indicated by 
the high value of the imprinting factor obtained. Although Sunitinib is always given in 
monotherapy without being co-administrated with other drugs, nevertheless the rebinding 
selectivity of MIP 1.5 was investigated using two common anticancer drugs : SN38 which has 
a similar shape and  size as sunitinib, and paclitaxel, a much large molecule. Under the same 
experimental conditions the cross reactivity of MIP1.5 with SN38 and paclitaxel was found to 
be 23% and 3% respectively. 
Fluorimetry 
The presence of tyrosine, tryptophan and coumarin in the different nanogel preparations allows 
fluorimetric evaluation of the binding affinity at low drug concentrations. We have studied first 
the emission spectra of the fluorescent nanogels in their colloidal solutions in both DMSO and 
then in mixtures of DMSO and water, as these are the conditions in which the nanogels are 
  
 
going to be applied. Characterisation techniques commonly used for bulk polymers or thin films 
could not be applied. The emission spectra for tyrosine and trypthopan containing nanogels are 
reported in the supplementary materials while the emission spectrum of MIP 1.5 is reported in 
Figure 3a. The emission of nanogels NIP 0.5 and MIP 1.5 is the highest, as expected given the 
high quantum yield of fluorescent tag. Monitoring of fluorescence over 30 hours provided 
evidence that the nanogels are photostable. Fluorescence quenching was indeed observed upon 
titration of all the polymeric nanogels with increasing concentrations of sunitinib. An example 
is reported in Figure 3a for MIP 1.5. The Stern-Volmer plots (Sarzehi and Chamani 2010) 
obtained with the tyrosine, tryptophan and coumarin MIPs show a bimodal quenching 
behaviour, with a first, higher slope, linear region at low concentrations of drug, and a second, 
lower slope, linear region at higher drug concentrations. Conversely, the Stern–Volmer plots 
reporting the fluorescence quenching of the free functional monomers upon titration with the 
drug show a single linear behaviour with a slope similar to the second region of the polymers 
(Table 1, Figure 3b for the coumarin derivatives, supplementary materials for the other 
compounds).   
 
 
 
 
 
  
 
 
     Figure 3 (new) 
The efficiency of the drug in quenching the MIPs emission was investigated by the Stern-
Volmer equation 1(Gao et al. 2014), which was separately applied on the two linear regions of 
the Stern-Volmer plots. 
                                                            𝐹0/𝐹 = 𝐾𝑆𝑉
𝑎𝑝𝑝 ∙ [𝑄] + 1  eq. 1 
. 
The Stern–Volmer constants are reported in Table 1, together with the bimolecular quenching 
constants kq
app calculated by equation 2: 
𝑘𝑞
𝑎𝑝𝑝 = 𝐾𝑆𝑉
𝑎𝑝𝑝/
0
  eq. 2 
where 0 is the lifetime of the fluorophores, which was assumed to be 4.3 ns for coumarin 
(Boens et al. 2007), 3.6 ns for tyrosine and 3.1 ns for tryptophan (Guzow et al. 2004; Szabo 
1980). Even when the lower slope regions of the plots are included,  kq
app is larger than the limit 
value for the diffusion controlled quenching (1·10-10 M-1s-1). Thus, the observed quenching must 
be the consequence of a static interaction,  i.e. the formation of a complex between the emitting 
polymers and the quencher drug ligand (Lakowicz 2006). The apparent Stern-Volmer constants 
  
 
can therefore be regarded as apparent association constant for the MIPs-target complexes. The 
high Stern-Volmer constants measured at drug concentrations lower than 5 M (Table 1) are 
most likely related to the presence of binding sites with a higher apparent binding affinity. 
Interestingly the concentration of such sites is very similar in all imprinted nanogels, suggesting 
that this is a feature likely to be related to the concentration of functional monomer and 
crosslinker used in the synthesis.  Conversely, lower affinity binding sites on the polymer 
surface may be associated to the second region of the plots where the slope is similar to that 
obtained in the titration of the free functional monomers (Table 1 and Figure 3b). The 
fluorescence quenching of polymer 1.5, containing the coumarin unit, can be clearly visualised 
also by naked-eye (Figure 3c and d). 
Detection of sunitinib in plasma 
MIP 1.5, being the best binder and having excellent fluorescence properties, was chosen as the 
fluorescent nanogel to be used for the development of a direct assay for sunitinib in plasma 
samples.  
Pre-treatment with a denaturing agent such as methanol or ethanol is generally required for the 
detection of drugs in plasma, where they are strongly associated to serum albumins. These 
common denaturing agents, however, cannot be used in this case, as the imprinted polymer 
releases the target drug when treated with alcohols. Thus, in this assay, DMSO has been used 
as denaturing agent. The action of DMSO on human plasma is very different from that of 
alcohol: the latter leads to the denaturation and precipitation of serum albumin, while DMSO 
leads to unfolding without precipitation (Sterling 2011, Tjernberg 2006). DMSO, however, is 
compatible with the imprinted polymer and we reasoned that serum albumin unfolding would 
be sufficient to release the albumin-bound drug. The designed assay thus requires simple 
dilution of the plasma sample in DMSO, addition of the fluorescent MIP and quantification of 
the fluorescence emission, which compared to a reference sample allows the quantification of 
the drug present in the plasma. 
  
 
A calibration curve was initially obtained by titrating 60 g/mL MIP 1.5 with increasing 
amounts of sunitinib in a 4:1 DMSO : water mixture (Figure 4a).  The titration was repeated in 
triplicate experiments carried out with different polymer preparations and repeated in different 
days. The average calibration curve obtained from these titrations (Figure 4a, full circles) 
shows an excellent precision, with a within-run variability (CV) lower than 9%, and an average 
within-day variability lower than 5%. From the apparent Stern-Volmer constant for MIP1.5 
(Table 1) and the observed variability, a value of 400 nM can be obtained as the lower limit of 
detection of sunitinib, defined as the lowest concentration of sunitinib leading to an emission 
of polymer fluorescence that can be statistically differentiated from the reference (average 
emission under 3 from the initial emission). As we have stated in the introduction there are no 
detection methods for sunitinib other than LC-MS. Clearly LC-MS is more sensitive than our 
system (which nevertheless is reported here as a non optimized proof of concept that could lead 
to more sensitive systems when exploited inside an optimized sensing device). However, our 
aim is to develop a system capable to detect plasma levels of sunitinib over the therapeutic 
range, and under this point of view, the sensitivity is satisfactory.   
 
   
                                      a                                                                   b             
Figure 4 (new) 
 
  
 
Samples spiked with known quantities of sunitinib in both PBS and normal human plasma were 
treated with four volumes of DMSO to unfold proteins. In plasma, this treatment led to the 
formation of a small amount of white precipitate likely due to salts (as no absorbance at 280 
nm was recorded after redissolving the precipitate in water). After centrifugation, MIP 1.5 was 
added from a mother solution in DMSO; the emission of the spiked samples was corrected for 
the emission of a plasma sample not containing sunitinib, and the  drug concentration was 
calculated from the calibration curve obtained in 4:1 DMSO : water (Figure 4). The real and 
calculated concentrations of the drug in the spiked samples are reported in Table 2. Despite the 
samples were quantified using a calibration curve obtained in a different medium (DMSO : 
water), the accuracy was encouraging, and the calculated concentrations correlate well with the 
theoretical ones in both PBS and plasma solutions. The slope of the linear regression of these 
data is very close to the theoretical value of 1 for both the plasma samples and the buffer-
albumin ones (Figure 4b). Therefore the robustness of the system upon changing the medium 
from DMSO : water to DMSO : PBS and DMSO : human plasma, is  good.  
 
4. Conclusions  
In conclusion, we have designed and synthesized a set of fluorescent MIPS that bind sunitinib 
with good sensitivity. We have also developed a novel analytical protocol for the fluorimetric 
sensing of sunitinib in plasma samples exploiting the quenching of the MIP fluorescence by 
bound sunitinib. Simple dilution of human plasma with DMSO allows the detection of the drug 
with MIP 1.5. The encouraging results obtained with this proof of concept open the way to the 
possible use of a fluorescent MIP as sensor for monitoring drug concentration directly in plasma 
with minimal sample treatment. We are currently working on portable fluorimetric systems 
based on this method, to be used as point of care devices. 
 
Acknowledgements 
  
 
We acknowledge the AIRC 5x1000 grant “Application of Advanced Nanotechnology in the 
Development of Innovative Cancer Diagnostics Tools”. We thank Dr G. Mastroianni for the 
TEM data. 
 
5. References 
Andriamanana, I., Gana, I., Duretz, B., Hulin, A., 2013. J. Chromotogr. B 926, 83-91. 
Alnaim, L., 2007. J. Oncol. Pharm. Practice. 13, 207–221. 
Altintas, Z., Guerreiro, A., Piletsky, S.A., Tothill, I.E., 2015. Sensors and Actuators B. 213, 
305–313.  
Athikomrattanakul, U., Katterle, M., Gajovic-Eichelmann, N., Sheller, F.W., 2009. Biosens. 
Bioelectron. 25, 82-87. 
Awino, J.K., Zhao, Y., 2014. Chem. Commun. 50, 5752. 
Bentolila, A., Vlodavsky, I., Ishai-Michaeli, R., Kovalchuk, O., Haloun, C., Domb, A.J., 2000. 
J. Med. Chem. 43, 2591-2600. 
Blanchet, B., Saboureau, C., Benichou, A.S., Billemont, B., Taieb, F., Ropert, S., Dauphin, A., 
Goldwasser, F., Tod, M. 2009. Clin. Chim. Acta 404, 134-139. 
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Tables 
 
 
Table 1: physical and binding properties of the MIPs. 1DLS size number measured in a 10% water:DMSO 
mixture on 250 g/mL colloidal solutions of nanogels (NIP 0.2 was dissolved in DMSO only due to its poor 
solubility in the water mixture. 2Rebinding measured by HPLC on a 50 M solution containing 1 mg/mL 
polymer. 3Apparent Stern-Volmer constant measured at ligand concentrations below and (above) 5M. The 
Stern-Volmer constants measured for the interactions of 1 with fluorophores 3a, 4a and 5a were 12.7, 12.2 and 
18.4 respectively. 4Apparent quenching constants measured at ligand concentrations below and (above) 5M. 
The quenching constants measured for the interactions of 1 with fluorophores  3a, 4a and 5a were 3.5, 3.9 and 
4.3 respectively.  
Nanogel Functional 
monomer 
Crosslinker 
(%) 
DLS Size 
Number1 
(nm) AVG 
PDI Rebinding2 
nmol mg-1 
IF Ksv
3 
103Lmol-1 
kq
4 
1012Lmol-1 s-1 
MIPs 
1.2 2 70 8.10±2.5 0.65 19 6 - - 
1.3 3b 70 11.6±2.5 1 14 3 37.6 (14.4) 10.4 (4.0) 
1.4 4b 70 11.9±3.7 0.35 20 3 25.2 (10.7) 8.1 (3.5) 
1.5 5b 70 12.5±3.3 0.50 42 6 61.0 (15.5) 14.2 (3.6) 
NIPs        
0.2 2 70 203±25 1 3    
0.3 3b 70 10.5±2.0 0.25 4    
0.4 4b 70 14.7±4.1 0.51 6    
0.5 5b 70 13.7±4.1 0.54 7  26.5 (8.2) 6.2 (1.9) 
 
 
Table 2: Real and calculated sunitinib concentrations in spiked samples 
 
Real sunitinib 
concentration  
[10-6 mol·L-1] 
Calculated sunitinib concentration [10-6 mol·L-
1] 
In PBS with 50 mg·mL-1 HSA  In plasma 
5 5.12 3.75 
20 14.7 - 
50 51.6 58.9 
80 69.2 - 
 
 
Captions to Figures 
 
Figure 1: Structures of sunitinib and of functional monomers; changes in the chemical shifts of 
selected protons of the target drug upon addition of the functional monomers (at a 1:14 molar 
ratio). The titrations were carried out in DMSO-d6 at room temperature. 
 
Figure 2: TEM image of MIP 1.5 over a graphene oxide grid 
Figure 3: a)  Emission spectrum of MIP 1.5 (60 g/mL) alone and upon addition of increasing 
concentrations of sunitinib. b) Stern-Volmer plots of the emissions of MIP 1.5, NIP 0.5 and 7-
hydroxycoumarin upon addition of increasing concentrations of sunitinib. cI) picture of a 60 
µg/mL solution of MIP 1.5 upon excitation with a 365 nm UV lamp. cII) picture of the same 
solution after addition of  50 µM sunitinib; d) Picture of a spot of 25 µg MIP 1.5 on filter paper 
before and after the addition of 300 ng of sunitinib. 
 
Figure 4: a) distribution of the spiked samples in PBS with 50 mg/mL HSA and in human 
plasma on the calibration curve; b) correlation between the calculated sunitinib concentration 
and the real drug concentration of spiked samples in PBS with 50 mg/mL HSA and in plasma; 
dotted line: identity; full line: regression.  
